Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.

ABSTRACT:

Aims

Treosulfan is an alkylating agent increasingly used prior to haematopoietic stem cell transplantation. The aim of this study was to develop a population pharmacokinetic (PK) model of treosulfan in paediatric haematopoietic stem cell transplantation recipients and to explore the effect of potential covariates on treosulfan PK. Also, a limited sampling model (LSM) will be developed to accurately predict treosulfan exposure suitable for a therapeutic drug monitoring setting.

Methods

In this multicentre study, 91 patients, receiving a total dose of 30, 36 or 42 g/m² treosulfan, administered over 3 consecutive days, were enrolled. A population PK model was developed and demographic factors, as well as laboratory parameters, were included as potential covariates. I

SUBMITTER: van der Stoep MYEC 

PROVIDER: S-EPMC6710524 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature